In a diseased state, can a drug glide the immune-system from one MHC phenotype to another?

At different time points, if it is possible to observe shift in MHC-phenotype (MHC1 to MHC2 and/or vice-versa) due to pharmaceutical intervention during cancer treatment?

10 October 2019 7,312 3 View